Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome

Anti-Cancer Drugs

Volumn 10, Issue 3, 1999, Pages 289-291

  Tanaka, Masatsugu ^b   Kanamori, Heiwa ^b   Yamaji, Satoshi ^b   Mishima, Aki ^b   Fujita, Hiroyuki ^b   Fujisawa, Shin ^b   Murata, Takashi ^b   Koharazawa, Hideyuki ^a   Matsuzaki, Michio ^a   Mohri, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Adverse effects; Allergic reaction; Low dose cytosine arabinoside

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; FEMALE; HUMAN; LIVER DYSFUNCTION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; LIVER FAILURE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 0032772805     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199903000-00006     Document Type: Article

References (12)

1. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of cancer and leukemia group B. Blood 1991; 78: 2520-6.
2. Schiller G, Gajewski J, Territo M, et al. Long-term oucome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977-82.
3. Housset M, Daniel MT, Degos L. Small doses of Ara-C in the treatment acute myeloid leukaemia: differentiation of myeloid leukaemia cell? Br J Haematol 1982; 51: 125-9.
4. Bolwell BJ, Cassileth PA, Gale P. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1987; 1: 575-9.
5. Kumar L, Kochupillai V, Dua H. Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia. Cancer 1989; 63: 415-8.
6. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 1985; 55: 1633-6.
7. Kanamori H, Maruta A, Miyashita H, et al. Low-dose cytosine arabinoside for treating hypocellular acute leukemia in the elderly. Am J Hematol 1992; 39: 52-5.
8. Stentoft J. The toxicity of cytarabine. Drug Safety 1990; 5: 7-27.
9. Rassiga AL, Schwartz HI, Forman WB, Crun ED. Cytambine-induced anaphylaxis. Arch Intern Med 1980; 140: 425-6.
10. Kantarjian H, Barlogie B, Plunkett W, et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1983; 1: 689-94.
11. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alteration in sequential chemotherapeutic protocols. A clinical pathological study of 33 patients. Cancer 1978; 42: 1747-59.
12. Healy HG, Clarkson AR. Renal complications of cytotoxic therapy. Aust NZ J Med 1983; 13: 531-9.